Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Globus Medical, Inc. (NYSE:GMED). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $15,001 and $50,000 in Globus Medical stock on August 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
- Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
- Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
- Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
- Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
- Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
- Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.
Globus Medical Trading Up 0.9%
Shares of NYSE:GMED opened at $74.21 on Friday. The firm has a market capitalization of $9.96 billion, a PE ratio of 18.98, a PEG ratio of 1.18 and a beta of 0.95. Globus Medical, Inc. has a 1-year low of $54.15 and a 1-year high of $101.40. The business’s 50 day moving average is $80.40 and its 200-day moving average is $83.82.
Hedge Funds Weigh In On Globus Medical
Institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System grew its stake in Globus Medical by 7,827.7% in the second quarter. California State Teachers Retirement System now owns 10,326,607 shares of the medical device company’s stock valued at $815,905,000 after purchasing an additional 10,196,347 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after buying an additional 3,595,339 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after buying an additional 1,908,795 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in Globus Medical during the fourth quarter worth $90,411,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on GMED shares. BMO Capital Markets assumed coverage on shares of Globus Medical in a research report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 target price for the company. Truist Financial reduced their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Piper Sandler dropped their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a report on Monday, June 15th. Finally, Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $101.77.
Check Out Our Latest Research Report on Globus Medical
Insider Transactions at Globus Medical
In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the sale, the director owned 25,000 shares in the company, valued at $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 18.38% of the company’s stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Globus Medical
Globus Medical, Inc (NYSE: GMED) is a medical device company that develops, manufactures and markets musculoskeletal solutions for surgeons, hospitals and patients. Its primary focus is spinal surgery, supported by a portfolio of implants, instruments and enabling technologies designed to assist with procedures involving the cervical, thoracic and lumbar spine.
The company’s products include spinal fusion systems, interbody devices, deformity correction systems, biologics and surgical instruments.
Recommended Stories
- Five stocks we like better than Globus Medical
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
